Evicenter
P&T meetings

Anaphylm (dibutepinephrine)

Type I allergic reactions including anaphylaxis

Also known as AQST-109
Regulatory submission
NDA resubmitted September 2026
Launch
Not announced
Last updated
121 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

21 evidence topics · 13 sources

Phase 1 single ascending dose study: 12 mg film formulations versus EpiPen
PK parameterAQST-109 F1, 12 mg (N=6)AQST-109 F2, 12 mg (N=8)0.3 mg IM EpiPen (N=10)
Geometric mean Cmax, pg/mL“552”“762”“341”
Median Tmax, minutes“15”“15”“22”
AUC 0-t, hr*pg/mL“634”“603”“328”
Confirmatory pharmacokinetic study: self-administration versus clinician administration and manual intramuscular epinephrine
DescriptionAnaphylm self-administeredAnaphylm clinician-administeredManual IM clinician-administered
Geometric mean Cmax, pg/mL“391.7”“357.6”“334.5”
Median Tmax, minutes“12”“12”“45”
Oral allergy syndrome study: single-dose maximum concentration and time to maximum concentration
AdministrationCmax, pg/mLMedian Tmax, minutes
Manual IM (n=24)“261.2”“50”
Anaphylm with allergen (n=23)“403.5”“12”
Anaphylm without allergen (n=15)“372.8”“12”
Oral allergy syndrome study: repeat-dose maximum concentration and time to maximum concentration
AdministrationCmax, pg/mLMedian Tmax, minutes
Manual IM (n=22)“538.8”“57.5”
Anaphylm with allergen (n=23)“1194.0”“25”
Anaphylm without allergen (n=13)“585.5”“25”